An international validation study of the IL-2 Luc assay for evaluating the potential immunotoxic effects of chemicals on T cells and a proposal for reference data for immunotoxic chemicals.
IL-2
Immunotoxic assay
Luciferase assay
Validation study
Journal
Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
06
01
2020
revised:
12
03
2020
accepted:
17
03
2020
pubmed:
23
3
2020
medline:
11
3
2021
entrez:
23
3
2020
Statut:
ppublish
Résumé
To evaluate the immunotoxic effects of xenobiotics, we have established the Multi-ImmunoTox assay, in which three stable reporter cell lines are used to evaluate the effects of chemicals on the IL-2, IFN-γ, IL-1β and IL-8 promoters. Here, we report the official validation study of the IL-2 luciferase assay (IL-2 Luc assay). In the Phase I study that evaluated five coded chemicals in three sets of experiments, the average within-laboratory reproducibility was 86.7%. In the Phase II study, 20 coded chemicals were evaluated at multiple laboratories. In the combined results of the Phase I and II studies, the between-laboratory reproducibility was 80.0%. These results suggested that the IL-2 Luc assay was reproducible both between and within laboratories. To determine the predictivity, we collected immunotoxicological information and constructed the reference data by classifying the chemical into immunotoxic compounds targeting T cells or others according to previously reported criteria. When compared with the reference data, the average predictivity of the Phase I and II studies was 75.0%, while that of additional 60 chemicals examined by the lead laboratory was 82.5%. Although the IL-2 Luc assay alone is not sufficient to predict immunotoxicity, it will be a useful tool when combined with other immune tests.
Identifiants
pubmed: 32200032
pii: S0887-2333(20)30015-1
doi: 10.1016/j.tiv.2020.104832
pmc: PMC9552337
mid: NIHMS1660497
pii:
doi:
Substances chimiques
Immunologic Factors
0
Interleukin-2
0
Luciferases
EC 1.13.12.-
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
104832Subventions
Organisme : Intramural NIH HHS
ID : Z99 ES999999
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Immunotoxicol. 2005 Apr 1;2(2):61-83
pubmed: 18958661
Fundam Appl Toxicol. 1993 Jul;21(1):71-82
pubmed: 8365588
Toxicol Appl Pharmacol. 2011 Aug 1;254(3):245-55
pubmed: 21569788
Regul Toxicol Pharmacol. 2014 Feb;68(1):96-107
pubmed: 24280359
Toxicol In Vitro. 2001 Aug-Oct;15(4-5):313-8
pubmed: 11566555
Arch Toxicol. 2018 Jun;92(6):2043-2054
pubmed: 29594315
Fundam Appl Toxicol. 1988 Jan;10(1):2-19
pubmed: 3280374
Toxicol In Vitro. 2014 Aug;28(5):759-68
pubmed: 24603311
Altern Lab Anim. 2002 Nov-Dec;30(6):581-95
pubmed: 12513684
Toxicol Lett. 1992 Dec;64-65 Spec No:71-8
pubmed: 1471226
Fundam Appl Toxicol. 1992 Feb;18(2):200-10
pubmed: 1534777
Nat Immunol. 2011 Jun;12(6):551-9
pubmed: 21516110
Methods Mol Biol. 2010;598:401-23
pubmed: 19967527
Arch Toxicol. 2011 May;85(5):367-485
pubmed: 21533817
J Immunotoxicol. 2010 Oct-Dec;7(4):255-67
pubmed: 20735150